Angiopoiesis and bone regeneration via co-expression of the hVEGF and hBMP genes from an adeno-associated viral vector in vitro and in vivo

Chen ZHANG1, Kun-zheng WANG2, Hui QIANG1, Yi-lun TANG1, Qian LI2, Miao LI2, Xiao-qian DANG1, *

1Department of Orthopedic Surgery, 2Department of Ultrasound, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

Aim: To investigate the therapeutic potential of adeno-associated virus (AAV)-mediated expression of vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP).

Methods: Four experimental groups were administered the following AAV vector constructs: rAAV-hVEGF165-internal ribosome entry site (IRES)-hBMP-7 (AAV-VEGF/BMP), rAAV-hVEGF165-GFP (AAV-VEGF), rAAV-hBMP-7-GFP (AAV-BMP), and rAAV-IRES-GFP (AAV-GFP). VEGF165 and BMP-7 gene expression was detected using RT-PCR. The VEGF165 and BMP-7 protein expression was determined by Western blotting and ELISA. The rabbit ischemic hind limb model was adopted and rAAV was administered intramuscularly into the ischemic limb.

Results: Rabbit bone marrow-derived mesenchymal stem cells (BMSCs) were cultured and infected with the four viral vectors. The expression of GFP increased from the 7th day of infection and could be detected on the 28th day post-infection. In the AAV-VEGF/BMP group, the levels of VEGF165 and BMP-7 increased with prolonged infection time. The VEGF165 and BMP-7 secreted from BMSCs in the AAV-VEGF/BMP group enhanced HUVEC tube formation and resulted in a stronger osteogenic ability, respectively. In rabbit ischemic hind limb model, GFP expression increased from the 4th week and could be detected at 8 weeks post-injection. The rAAV vector had superior gene expressing activity. Eight weeks after gene transfer, the mean blood flow was significantly higher in the AAV-VEGF/BMP group. Orthotopic ossification was radiographically evident, and capillary growth and calcium deposits were obvious in this group.

Conclusion: AAV-mediated VEGF and BMP gene transfer stimulates angiogenesis and bone regeneration and may be a new therapeutic technique for the treatment of avascular necrosis of the femoral head (ANFH).

Keywords: adeno-associated virus; vascular endothelial growth factor; bone morphogenetic protein (BMP); avascular necrosis of the femoral head (ANFH); gene therapy

Acta Pharmacologica Sinica (2010) 31: 821–830; doi: 10.1038/aps.2010.67; published online 28 June 2010

Introduction

Recent insight into the pathogenesis of avascular necrosis of the femoral head (ANFH) has not identified satisfactory methods to increase blood circulation in necrotic areas of the femoral head, to promote bone regeneration, or to prevent osteonecrosis. The rapid development of gene therapy technology is increasingly recognized as a new therapeutic option for the treatment of ANFH, especially through therapeutic neovascularization and bone formation. Among growth factors, vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP) play important roles and have been extensively studied.

The VEGF family of growth factors is one of the most important cytokine families involved in angiogenesis. These factors promote the division of vascular endothelial cells and induce angiopoiesis. VEGF growth factors are essential for bone formation and repair during the bone regeneration process, which directly attracts endothelial cells and osteoclasts and enhances the differentiation of osteoblasts[1, 2]. BMP growth factors are the only signaling molecules that are individually sufficient for the induction of bone formation at orthotopic and heterotopic sites. They have defined roles in stimulating the proliferation and differentiation of mesenchymal and osteoprogenitor cells and have efficient bone induction activity[3, 4]. Because bone formation is a coordinated process involving the BMP and VEGF growth factors[5, 6], orchestrating the timing with which these two factors are expressed may greatly enhance this process.
Choosing a safe and effective vector system to transfer and correctly express a target gene during gene therapy is important. Several different strategies have been examined for the delivery of genes of interest, including the use of naked DNA or an adenoviral vector. Treatment with naked DNA is simple and well tolerated by the recipient organism due to its low toxicity and weak induction of immune responses. However, the transduction efficiency is significantly lower when compared with other methods. The adenovirus has frequently been the vector of choice for gene transfer because it is able to transduce a variety of cells with high efficiency. However, adenoviral vectors have major limitations, including a lack of sustained expression, the antigenicity of viral proteins that are targeted by both humoral immunity and cytotoxic T lymphocytes, and possible toxicity at high doses. However, there are many inherent features of the adeno-associated virus system that make it an attractive option as a human viral vector. AAV is a non-pathogenic, defective human parvovirus that requires the presence of a helper virus, such as adenovirus or herpes virus, for productive infection[7, 8]. Other advantages of this vector system include its low immunogenicity, its ability to transduce both dividing and non-dividing cells, the potential to integrate into specific sites, its ability to achieve long-term gene expression (even in vivo), and its broad tropism, allowing for the efficient transduction of diverse organs[9]. These features make AAV attractive and efficient for gene transfer in vitro and local injection in vivo.

To enhance neovascularization and bone regeneration during osteonecrosis therapy, we constructed adeno-associated viruses co-expressing hVEGF_{165} and hBMP-7 (rAAV-VEGF_{165}-IRES-BMP-7) and detected their effect on gene expression and biological activity in vitro and in vivo. These data demonstrate the synergistic action of these two genes and may provide a new therapeutic option for ANFH.

Materials and methods

Materials and reagents

The rAAV-hVEGF_{165}-IRES-hBMP-7 (AAV-VEGF/BMP), rAAV-hVEGF_{165}-GFP (AAV-VEGF), rAAV-hBMP-7-GFP (AAV-BMP), and rAAV-IRES-GFP (AAV-GFP) plasmids were constructed by Dr Xiang-hui HUANG. Human embryonic kidney cells-293 (HEK-293) and human umbilical vein endothelial cells (HUVECs) were obtained from the Department of Orthopedic Surgery in the Second Affiliated Hospital of Xi’an Jiaotong University. Male New Zealand rabbits (two months old, weighing 2.0–3.0 kg) were obtained from the experimental animal center of Xi’an Jiao Tong University. All animal protocols followed the recommendations and guidelines of the National Institutes of Health and were approved by the Xi’an Jiao Tong University Animal Care and Use Committee. The AAV helper-free system was obtained from Stratagene (La Jolla, CA, USA). A schematic representation of the structure of the plasmids in the AAV Helper Free System is provided in Figure 1A.

rAAV vector production

The construction of the rAAV-hVEGF_{165}-IRES-hBMP-7 (AAV-VEGF/BMP), rAAV-hVEGF_{165}-GFP (AAV-VEGF), rAAV-
hBMP-7-GFP (AAV-BMP), and rAAV-IRES-GFP (AAV-GFP) vectors was carried out as previously described\(^{[10]}\). The structure of the pAAV-hVEGF\(_{165}\)-IRES-hBMP-7 vector is shown in Figure 1B. IRES sequences were incorporated into the pAAV MCS to construct a bicistronic vector with two multiple cloning sites. Then, the hVEGF\(_{165}\) (Pubmed NM-003376) and hBMP-7 (Pubmed NM-001719) genes were inserted into the upstream and downstream MCS, respectively. The length of the bicistronic frame is 2.5 kb, which is within the capacity of the vector. The AAV helper-free system was used to generate recombinant AAV. HEK-293 cells were cultured in H-DMEM supplemented with 10% fetal bovine serum containing 20 mg/mL penicillin-streptomycin and incubated with 5% CO\(_2\) at 37 °C. The AAV vector was co-transfected with the pAAV-helper and pAAV-RC vectors into HEK 293 cells by a calcium phosphate method according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). A primary virus stock was collected 72 h after transfection and further concentrated and purified by chloroform/PEG8000 protocols\(^{[11]}\). The recombinant adeno-associated virus had a titer of 5.5×10\(^{11}\) vp/mL.

**Rabbit bone marrow-derived mesenchymal stem cells (BMSC) culture and rAAV infection in vitro**

Male New Zealand rabbits were used to obtain rabbit BMSCs. The cells were harvested by gently flushing the tibiae and femora with L-DMEM. Density gradient centrifugation and adherent screening methods were used to isolate BMSCs as previously described\(^{[12]}\). The cells were cultured in L-DMEM supplemented with 10% fetal bovine serum containing 20 mg/mL penicillin-streptomycin and incubated with 5% CO\(_2\) at 37 °C. Following the 3rd passage, BMSCs (5×10\(^4\) cells/well) were seeded onto 24-well plates 24 h before rAAV infection. By taking into account the cytopathogenic effect, infection efficiency, and cost of recombinant virus, we determined that the best multiplication of infection (MOI) for infecting rabbit BMSCs with rAAV was 5×10\(^4\) vp/cell. The four rAAV virus variants were introduced into BMSCs using this MOI. Cells were incubated as above and were swirled gently at 30-min intervals. One hour later, the medium was replaced with L-DMEM supplemented with 10% fetal bovine serum. Medium was then completely replaced every 3 days.

**Rabbit hind limb ischemia model and rAAV infection in vivo**

Male New Zealand rabbits were kept under specific pathogen free conditions and supplied with sterile food and acidified water. The hind limb ischemia model was developed as described previously\(^{[13]}\). Rabbits were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg). Under a surgical microscope, a vertical longitudinal incision was made in the right hind limb. The right femoral arteries were separated from the origin of the external iliac artery, ligated, and completely excised. Immediately after ligation of the femoral artery, the four rAAV virus variants were each injected into five different sites\(^{[14]}\) on the three major thigh muscles of each rabbit (5.5×10\(^3\) vp/20 µL per site), including the adductor (two sites), the quadriceps (two sites), and the semimembranosus (one site) muscles. Subsequently, the skin was sutured. After surgery, all animals were housed under standard conditions (temperature: 21±1 °C; humidity: 55%–60%) with food and water continuously available. The hind limbs were mobilized without any fixation. To prevent infection, animals received prophylactic injections of gentamicin (0.03 mg·kg\(^{-1}\)·d\(^{-1}\), im) within 3 days after surgery.

Rabbits were sacrificed at various time points post-injection to characterize gene expression efficiency and the effects on angiopoiesis and bone regeneration in vivo. Each group contained 30 rabbits and was divided into four experimental subgroups: group A (n=6) was examined at week 2 for GFP expression (n=3) and immunoblotting (n=3), group B (n=6) at week 4 for GFP expression (n=3) and immunoblotting (n=3), group C (n=9) at week 6 for GFP expression (n=3), immunoblotting (n=3), and ELISA (n=3), and group D (n=9) at week 8 for GFP expression (n=3) and for blood flow measurement, X-ray radiography, and immunohistochemistry (n=6).

**Reporter gene (GFP) expression in vitro and in vivo**

Following 3, 7, 14, and 28 days of infection with AAV-GFP virus in vitro, the expression of GFP protein was observed by inverted fluorescence microscopy. At 2, 4, 6, and 8 weeks post-injection in vivo, the muscles injected with the AAV-GFP virus were sliced by the frozen section method and the expression of the GFP protein was observed as above. Each assay was performed in triplicate.

**Preparation of culture medium and assessment of VEGF\(_{165}\) and BMP-7 gene expression**

Total cellular RNA was isolated at 1, 2, 3, 7, 14, 21, and 28 days following infection with the AAV-GFP, AAV-VEGF, AAV-BMP or AAV-VEGF/BMP viruses using TRIzol Reagent (Invitrogen). Extracted RNA was treated with DNase I (Takara, Tokyo, Japan) to eliminate DNA contamination, and first-strand cDNA was synthesized with random hexamer primers using the reverse first-strand cDNA synthesis kit from MBI Fermentas (Glen Burnie, MD, USA). PCR was performed to amplify humanVEGF\(_{165}\) (forward primer 5′-CCATCGATATGAACTTTTCTCTTGCTTGTT-3′; reverse primer 5′-CGGATATTCCACCGCCTCCTGCCTGTC-3′) and BMP-7 (forward primer 5′-GGCCGGATCCATGCACGTGCGCTCACTGCG-3′; reverse primer 5′-GGGGCGTGCACCTCAGTGGCATCCTGCG-3′) genes\(^{[16]}\). β-actin (forward primer 5′-GAGGGAAATCGTGACCTAGTGGCAGCCAGCCA-3′; reverse primer 5′-GGCCGGATCCATGCACGTGCGCTCACTGCG-3′) was used as an internal control. PCR was performed using the following program: 94 °C for 3 min for one cycle and 35 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 45 s. The PCR products were electrophoresed on ethidium bromide-stained 2.0% agarose gels. Each assay was performed in triplicate.

**Muscle extract preparation and assessment of VEGF\(_{165}\) and BMP-7 gene expression**

At 2, 4, and 6 weeks following injection with the AAV-GFP, AAV-VEGF, AAV-BMP, or AAV-VEGF/BMP viruses,
the frozen muscles were pulverized in liquid nitrogen and homogenized in 3 mL of ice-cold lysis buffer (1% Nonidet P-40, 50 mmol/L Tris-HCl, pH 7.4; 150 mmol/L NaCl; 200 U/mL aprotinin; 1 mmol/L phenylmethylsulfonyl fluoride, PMSF). The tissue lysates (50 mg of protein) were separated by 12% polyacrylamide gel electrophoresis and blotted onto polyvinylidene difluoride membranes. Immunoblotting was performed with anti-human VEGF<sub>165</sub> and BMP-7 antibodies and the specific binding of the antibody was visualized with an ECL detection system. At 6 weeks post-injection, muscle extracts were measured with an enzyme-linked immunosorbent assay (ELISA) kit using the Biotrak ELISA system (R&D, Minneapolis, MN, USA) according to the manufacturer’s instructions. Each assay was performed in triplicate.

**Angiogenic and osteogenic in vitro assays**

**Tube formation assay**
HUVECs were cultured as previously described<sup>[15]</sup>. Basement membrane matrigel matrix (BD, Bedford, MA, USA) was diluted by serum-free medium, added to a 24-well plate, and incubated at 37 °C for 30 min to allow solidification to occur. HUVECs (5×10<sup>4</sup> cells/well) were seeded on the matrigel and fresh L-DMEM medium supplemented with 10% FBS was added. Next, 1 mL of culture supernatant was harvested from the AAV-GFP, AAV-VEGF, AAV-BMP, or AAV-VEGF/BMP groups 14 days post-infection and added to the 24-well plate. The plate was then incubated at 37 °C with 5% CO<sub>2</sub> for 12 h. The images of tube formation were captured under a light microscope from three random fields, and quantification of the tubes was analyzed by image processing software (Media Cybernetics, USA) to assess the biological activity of VEGF in vitro.

**Mineralization assay**
BMSCs were infected with the four virus groups above. The cells were then cultured in L-DMEM supplemented with 10% fetal bovine serum containing 20 mg/mL penicillin-streptomycin with 5% CO<sub>2</sub> at 37 °C (the culture medium did not contain osteogenic induction factors, such as ascorbic acid, β-glycerophosphate, or dexamethasone). Mineralization effects were detected by von Kossa and alizarin red (AZR) staining<sup>[16]</sup> for calcium deposits 4 weeks post-infection and observed using an inverted phase contrast microscope. The images of mineral nodules were captured under a light microscope from three random fields, and quantification of the mineral nodules was analyzed by image processing software to assess the biological activity of BMP in vitro.

**Blood flow measurement and orthotopic bone formation in vivo**
Eight weeks after injection, eight rabbits in the four groups were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg). Blood flow in the anterior tibial artery of ischemic and normal hind limbs was measured at rest with an Aspen Advanced Doppler ultrasound device from Acuson (Siemens Medical Solutions, Mountain View, CA, USA) using a perivascular flow probe and calculated by the inlay automatic processing software. The data were expressed as a percentage of the contralateral limbs. Three separate measurements were performed for each rabbit at every time point and the results were averaged. In addition, rabbits in the four groups were subjected to X-ray radiography to assess orthotopic bone formation.

**Histological assessment**
Eight weeks after injection, thigh muscle tissue sections of ischemic limbs from the four groups were harvested and fixed in 10% neutral-buffered formalin. To identify the proliferation of capillary endothelial cells, tissue sections were immunostained for CD34. The monoclonal antibody against CD34 was applied at a 1:500 dilution after blocking with 1% normal bovine serum. Subsequent incubation with biotinylated horse anti-mouse IgG and an ABC Elite kit (Santa Cruz) was performed. The number of CD34-positive vessels was counted at a magnification of 200×, and twenty fields from each typical slide were counted (mean number of capillaries per square millimeter). To assess orthotopic bone formation, the slides were stained by von Kossa staining to detect mineralization.

**Statistical analysis**
The results are reported as means±standard deviation. The normality of the data distribution was assessed with the Shapiro-Wilk (W) test. ANOVA followed by the Fisher’s test was conducted to assess differences among treatment groups. Statistical significance was set at a P-value less than or equal to 0.05. The SPSS mathematical statistics software used for this analysis was purchased from SPSS Inc (version 8; SPSS Inc, Chicago, IL, USA).

**Results**

**Animal condition after rAAV infection**
There were no symptoms of local or systemic toxicity after rAAV infection. In the region of the injection sites, no inflammatory reaction, such as rubeosis, engorgement, or abscess, was observed. The activities of all animals were normal. There was no systemic toxicity, such as nutation, instability of gait, anhelation, retardation, cyanosis, or convulsion. No animals died before the end of the experiments.

**GFP gene expression**

*In vitro*: GFP protein expression could be detected on the third day post-infection. However, the efficiency and density of infection were unstable. The expression of GFP protein increased from the 7th day and could be detected at 28 days post-infection (Figures 2A, 2B). *In vivo*: With prolonged infection time, GFP protein expression increased from the 4th week and could be detected at 8 weeks post-infection (Figures 2C, 2D).

**Efficient genes expression of hVEGF<sub>165</sub> and hBMP-7**
To confirm hVEGF<sub>165</sub> and hBMP-7 gene expression in vitro, RT-PCR assays were performed. As shown in Figure 3A–3D, the sizes of the PCR products for VEGF<sub>165</sub> and BMP-7,
and β-actin were 600 bp, 1300 bp, and 340 bp, respectively. With prolonged infection time, the intensity of the VEGF$_{165}$ and BMP-7 bands increased in the AAV-VEGF/BMP group. Together, these data demonstrate that VEGF$_{165}$ was expressed in the AAV-VEGF and AAV-VEGF/BMP groups but not in the AAV-BMP and AAV-GFP groups and that BMP-7 was expressed in the AAV-BMP and AAV-VEGF/BMP groups but not in the AAV-VEGF and AAV-GFP groups. Protein expression of 2, 4, and 6 weeks following injection with AAV-VEGF/BMP in vivo is shown in Figure 3E–3H. Expression of the VEGF$_{165}$ and BMP-7 proteins was visualized by Western blot analysis. Strong staining at the expected molecular weights of 23 kDa (hVEGF$_{165}$), 55 kDa (hBMP-7), and 43 kDa (β-actin) was observed. With prolonged infection time, the intensity of the VEGF$_{165}$ and BMP-7 bands increased. These data demonstrate that VEGF$_{165}$ was expressed in the AAV-VEGF and AAV-VEGF/BMP groups but not in the AAV-BMP and AAV-GFP groups and that BMP-7 was expressed in the AAV-BMP and AAV-VEGF/BMP groups but not in the AAV-VEGF and AAV-GFP groups. As shown in Figure 3I, 3J, the production of hVEGF$_{165}$ and hBMP-7 was quantified in relevant muscle extracts 6 weeks post-injection. The average amounts of hVEGF$_{165}$ protein in the AAV-VEGF/BMP and AAV-VEGF groups were significantly higher than those in the AAV-GFP and AAV-VEGF groups (P<0.05, n=30).

Biological activity of hVEGF$_{165}$ and hBMP-7 in vitro
As shown in Figure 4A, hVEGF$_{165}$ secreted from BMSCs in the AAV-VEGF/BMP group enhanced HUVEC migration, proliferation, and tube formation in comparison with the other three groups. The number of tubes in the AAV-VEGF/BMP group was significantly higher than that in the AAV-GFP and AAV-BMP groups. However, there was no statistical difference between the AAV-VEGF/BMP group and the AAV-VEGF group (Figure 4B). In addition, the mineralization effect of hBMP-7 was detected by von Kossa (Figure 5A) and alizarin red staining (Figure 5B). The AAV-VEGF/BMP group displayed stronger osteogenic activity than all the other groups. The number of mineralized nodules in the AAV-VEGF/BMP group was significantly higher than that in the AAV-GFP and AAV-BMP groups. However, there was no statistical difference between the AAV-VEGF/BMP group and the AAV-BMP group (Figure 5C).

Biological activity of hVEGF$_{165}$ and hBMP-7 in vivo
The ability of hVEGF$_{165}$ and hBMP-7 to induce tube formation and mineralization in vitro correlated well with their in vivo role in neovascularization and bone regeneration. Blood flow in the anterior tibial artery of ischemic and normal hind
limbs was measured 8 weeks post-injection to assess the neo-vascularization capability of hVEGF<sub>165</sub> in vivo. As shown in Figure 6, the ratio of mean ischemic/normal blood flow in the AAV-VEGF/BMP group was highest when compared with the AAV-GFP, AAV-VEGF, and AAV-BMP groups. However, there was no statistical difference between the AAV-VEGF/BMP group and the AAV-VEGF group. In addition, rabbits in the four groups were subjected to X-ray radiography to assess the bone regeneration activity of hBMP-7 in vivo. As shown in Figure 7, orthotopic ossification was radiographically evident in the AAV-VEGF/BMP group eight weeks post-injection. In contrast, no radiographic evidence of bone formation was observed in the AAV-GFP group or the AAV-VEGF group.

**Histological assessment**

To further assess vascularity in rAAV-infected muscle, immunostaining for CD34, a marker of vessel endothelial cells, was performed to detect the number of capillaries. As shown in Figure 8A, muscle from the AAV-VEGF/BMP group contained significantly more capillaries when compared with the other three groups at 8 weeks post-injection. The mean density of capillaries in the AAV-VEGF/BMP group was significantly higher than that in the AAV-GFP and AAV-BMP groups. However, there was no statistical difference between the AAV-VEGF/BMP group and the AAV-VEGF group (Figure 8C). To analyze bone formation, von Kossa staining was adopted to assess calcium deposits 8 weeks post-injection. As shown in Figure 8B, calcium deposits stained black. The osteogenic ability of the AAV-VEGF/BMP group was significantly enhanced compared with that found in the other three groups.

**Discussion**

The packaging capacity of the rAAV vector (5 kb, including the inverted terminal repeats) remains one of its primary limitations in terms of gene delivery. However, substantial progress has recently been made to overcome this restriction. Among the several different strategies to co-express multiple
genes, the incorporation of an IRES into this gene therapy vector represents one of the more promising strategies\textsuperscript{[17–19]}. The IRES functions as a ribosome landing pad for the efficient internal initiation of translation, ensuring coordinated expression of several genes. The IRES initiates ribosome binding and translation in the absence of a 5’CAP, thus overcoming the main disadvantage of traditional strategies that express two different genes. This characteristic is especially useful for AAV production due to the packaging size limitation imposed by the AAV vectors. In our current study, an IRES sequence was incorporated into the pAAV MCS to construct a bicistronic vector. Then, the hVEGF\textsubscript{165} and hBMP-7 genes were inserted upstream and downstream of the MCS, located on either side of the IRES to create a bicistronic frame of 2.5 kb in length, which is within the capacity of the vector. In our study, we reveal that AAV-mediated hVEGF\textsubscript{165} and hBMP-7 gene transfer \textit{in vitro} and \textit{in vivo} induces the expression and secretion of the hVEGF\textsubscript{165} and hBMP-7 proteins. These results demonstrate that the IRES sequence may be a superior strategy for co-expressing multiple genes in rAAVs.

An important characteristic of rAAV is that when the host cell is infected with rAAV, the efficiency of infection cannot immediately be determined. The expression of the gene of interest will not be activated until the double-stranded nucleic acid version of the virus has been synthesized by DNA synthetase. The time required for this to occur may be several days, weeks, or months and is dependent on the infection surrounding the host cells\textsuperscript{[20]}. For this reason, it is essential to detect the timing of gene expression \textit{in vitro} and \textit{in vivo}. The results of GFP expression and RT-PCR analysis \textit{in vitro} and of Western blotting and ELISA assays \textit{in vivo} revealed expression of the genes of interest, indicating that the rAAV vector has superior gene expressing ability.

The key aim of gene therapy for osteonecrosis disease is bone and vessel regeneration. Bone restoration is a compli-

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{4.png}
\caption{Tube formation experiment with HUVECs. (A) Representative images of tube formation. The HUVECs of AAV-VEGF/BMP group displayed stronger migration, proliferation, and tube formation ability than other three groups (magnification×200). (B) The data is expressed as the mean±SD from three independent experiments. \( ^*p<0.05 \) vs AAV-GFP group. \( ^{\text{\textdagger}}p<0.05 \) vs AAV-BMP group.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{5.png}
\caption{Osteogenic assay with BMSCs. (A) Representative images of von Kossa staining. BMSCs were stained by the von Kossa method and the mineralization is seen as black dots. (B) Representative images of alizarin red staining. BMSCs were stained by the alizarin red method and the mineralization is seen as mineralized nodules. (C) The data is expressed as the mean±SD from three independent experiments. (magnification×400). \( ^*p<0.05 \) vs AAV-GFP group. \( ^{\text{\textdagger}}p<0.05 \) vs AAV-VEGF group.}
\end{figure}
cated process involving many kinds of cytokines, and VEGFs and BMPs play important roles during renovation that have been studied extensively. VEGF is one of the most important cytokines in angiogenesis. It specifically promotes the division and growth of vascular endothelial cells and ultimately induces angiopoiesis [2, 4, 18, 20, 21]. BMPs are the only signaling molecules that can singly induce de novo bone formation at orthotopic and heterotopic sites. BMPs have discrete effects on the proliferation and differentiation of mesenchymal cells and osteoprogenitor cells and also have efficient bone induction activity [3, 22]. Thus, orchestrating the timing of expression of these two factors may greatly enhance this process.

We performed angiogenic and osteogenic assays to identify the biological effect of VEGF_{165} and BMP-7 in vitro and in vivo. The results indicated that at the dosage used, the rAAV-hVEGF_{165}-IRES-hBMP-7 virus had excellent biological activity and could properly mediate biological activity both in vitro and in vivo. However, one interesting finding of our study was that VEGF alone is not sufficient to improve bone formation and that BMP alone is not sufficient to improve vessel regeneration. We conclude that these findings were not due to improper dosage, but reflect the fact that expression of VEGF
or BMP alone is not sufficient to initiate the cascade of bone formation or vessel regeneration, respectively. These findings also demonstrate that orchestrating the expression of these two factors is essential for effective therapy of osteonecrosis disease. An additional interesting finding in our studies was that there was no statistical difference between the AAV-VEGF/BMP group and the AAV-VEGF group in terms of angiogenesis. Similarly, there was no statistical difference between the AAV-VEGF/BMP group and the AAV-BMP group in terms of bone formation. We conclude that there may be a requirement for the proper ratio of VEGF to BMP. As shown by a previous study\cite{23}, the proper ratio of VEGF to BMP is critical to ensure synergistic effects. In addition, the unequal expression of the VEGF and BMP genes located upstream and downstream of the IRES may be responsible\cite{24}. Thus, comparison of the expression of genes located upstream and downstream of the IRES and the identification of the best ratio of VEGF and BMP for treatment of osteonecrosis will be imperative in future experiments.

In summary, we used rAAV as a gene transduction system by successfully inserting the VEGF\textsubscript{165} and BMP-7 genes in this vector, allowing them to be efficiently and stably co-expressed. The VEGF\textsubscript{165} and BMP-7 proteins that were expressed from the rAAV-hVEGF\textsubscript{165}-IRES-hBMP-7 vector enhanced angiogenesis and bone regeneration \textit{in vitro} and \textit{in vivo}. Our experiments establish a foundation for investigating the synergistic biological effects of VEGF\textsubscript{165} and BMP-7 \textit{in vitro} and \textit{in vivo} and provide theoretical support for gene therapy of ANFH with our recombinant virus.

**Acknowledgements**

This work was supported by the National Natural Science Foundation of China (No 30600624) and (No 30772189).

We acknowledge the support of Xi’an Jiao Tong University. We are grateful to Dr Xiang-hui HUANG (Department of Orthopedics, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi Province, China) for his help in the construction of the rAAV-hVEGF\textsubscript{165}-IRES-hBMP-7 viral vector.

**Author contribution**

Chen ZHANG designed and performed the experiments; Kunzheng WANG, Hui QIANG, Yi-lun TANG contributed to the \textit{in vitro} studies; Qian LI and Miao LI contributed to the blood flow measurement studies; Xiao-qian DANG assisted in the design of the study, reviewed all data, and assisted in writing the manuscript. All authors have read and approved the final manuscript.

**References**

1 Dai J, Rabie AB. VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res 2007; 86: 937–50.
2 Clarkin CE, Emery RJ, Pitsillides AA, Wheeler-Jones CP. Evaluation of
VEGF-mediated signaling in primary human cells reveals a paracrine action for VEGF in osteoblast-mediated crosstalk to endothelial cells. J Cell Physiol 2008; 214: 537–44.

3 Hu J, Qi MC, Zou SJ, Li JH, Luo E. Callus formation enhanced by BMP-7 ex vivo gene therapy during distraction osteogenesis in rats. J Orthop Res 2007; 25: 241–51.

4 White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, McKee MD. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 2007; 31: 735–41.

5 Hou H, Zhang X, Tang T, Dai K, Ge R. Enhancement of bone formation by genetically-engineered bone marrow stromal cells expressing BMP-2, VEGF and angiopoietin-1. Biotechnol Lett 2009; 31: 1183–9.

6 Young S, Patel ZS, Kretlow JD, Murphy MB, McKee MD. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 2007; 31: 735–41.

7 Merten OW, Gény-Fiamma C, Douar AM. Current issues in adeno-associated viral vector production. Gene Ther 2005; 12: S51–61.

8 Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc 2006; 1: 1412–28.

9 Tu L, Xu X, Wan H, Zhou C, Deng J, Xu Q, et al. Delivery of recombinant adeno-associated virus-mediated human tissue Kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther 2008; 19: 318–30.

10 Huang X, Shi Z, Wang K, Dang X, Yang P, Yu P. Construction of recombinant adeno-associated virus vector co-expressing hVEGF165 and hBMP-7 genes. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2008; 22: 807–13. Chinese.

11 Yan H, Guo Y, Zhang P, Zu L, Dong X, Chen L, et al. Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors. Biochem Biophys Res Commun 2005; 336: 287–98.

12 Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284 (5411): 143–7.

13 Silvestre JS, Tamarat R, Ebrahimian TG, Te-Roux A, Clergue M, Emmanuel F, et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 2003; 93: 114–23.

14 Byun J, Heard JM, Huh JE, Park SJ, Jung EA, Jeong JO, et al. Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. J Mol Cell Cardiol 2001; 33: 295–305.

15 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 1973; 52 (11): 2745–56.

16 Bellows CG, Aubin JE, Heersche JN, Antosz ME. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 1986; 38: 143–54.

17 Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 1998; 334: 320–5.

18 Li W, Thakor N, Xu EY, Huang Y, Chen C, Yu R, et al. An internal ribosomal entry site mediates redox-sensitive translation of Nrf2. Nucleic Acids Res 2010; 38: 778–88.

19 Jeffrey S, Kieft. Viral IRES RNA structures and ribosome interactions. Trends Biochem Sci 2008; 33: 274–83.

20 Tang X, Fu DH, Yang SH, Ren YC, Li G, Yu CN, et al. Assessment of the expression profile during the entodochorostosis of vascular endothelial growth factor in bone morphogenetic protein 2 induced osteogenesis. Zhonghua Wai Ke Za Zhi 2008; 46: 614–7.

21 Samee M, Kasugai S, Kondo H, Ohy K, Shimokawa H, Kuroda S. Bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) transfection to human periosseous cells enhances osteoblast differentiation and bone formation. J Pharmacol Sci 2008; 108: 18–31.

22 Stöve J, Schneider-Wald B, Scharf HP, Schwarz ML. Bone morphogenetic protein 7 (BMP-7) stimulates proteoglycan synthesis in human osteoarthritic chondrocytes in vitro. Biomed Pharmacother 2006; 60: 639–43.

23 Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, et al. Synergistic enhancement of bone formation and healing by stem cell–expressed VEGF and bone morphogenetic protein-4. J Clin Invest, 2002; 110: 751–9.

24 Kapturczak M, Zolotukhin S, Cross J, Pliege A, Molano RD, Jorgensen M, et al. Transduction of human and mouse pancreatic islet cells using a bicistronic recombinant adeno-associated viral vector. Mol Ther 2002; 5: 154–60.